安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- FDA approves durvalumab for limited-stage small cell lung cancer
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed
- Immunotherapy for Small Cell Lung Cancer
Learn about immunotherapy for small cell lung cancer here Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S et al Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study J Clin Oncol 2017 Dec 1;35(34):3823-3829
- Imfinzi Improves Survival in Small Cell Lung Cancer - NCI
While targeted therapies have had less success for small cell than for non-small cell lung cancer, immunotherapy is a somewhat different story Over the past 5 years, durvalumab and two other immunotherapies— atezolizumab (Tecentriq) and tarlatamab (Imdelltra) —have been approved for the treatment of people with advanced, or extensive-stage
- New Treatment Approved for Patients with Extensive Stage Small Cell . . .
On May 16, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of tarlatamab-dlle (Imdelltra®) to treat patients with extensive stage small cell lung cancer (SCLC) This targeted immunotherapy, the first of its kind, is based on new technology
- Small-Cell Lung Cancer: Types of Immunotherapy - WebMD
Immunotherapy is a new treatment option for small-cell lung cancer Learn about the different types and how they work There are several FDA-approved immunotherapy drugs for SCLC, including:
- FDA approvals in lung cancer treatment
2021 October FDA approved atezolizumab (Tecentriq®) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage 2 to 3A NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells Link; September FDA approved mobocertinib (Exkivity®) for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion
- Imfinzi approved in the US as first and only immunotherapy regimen for . . .
Imfinzi is now the only immunotherapy approved for both limited- and extensive-stage small cell lung cancer, underscoring our commitment to improving survival rates ” Dusty Donaldson, Founder and Executive Director of LiveLung, said: "This new treatment option is a game changer for patients with limited-stage small cell lung cancer, a disease
- First Immunotherapy Approval for Limited-stage Small Cell Lung Cancer
The FDA approved durvalumab for some patients with previously treated limited-stage small cell lung cancer The U S Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) that did not progress after platinum-based chemotherapy and radiation This is the first FDA immunotherapy approval for patients
|
|
|